{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Body temperature Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"57"}]}],"title":"Weight Increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"}]}],"title":"Weight Decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83"}]}],"title":"Increased Heart Rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"Decreased Heart Rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"Increased Systolic Blood Pressure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"Decreased Systolic Blood Pressure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"Increased Diastolic Blood Pressure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"84"}]}],"title":"Decreased Diastolic Blood Pressure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}],"title":"Increased Respiratory Rate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}],"title":"Decreased Respiratory Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"Vital signs including body temperature, body weight, respiratory rate, heart rate (after 5-minute rest), and arterial blood pressure (after 5-minute rest) were evaluated. Number of participants with clinically significant abnormalities in Vital Signs reported as TEAEs. Clinically Significance was decided by investigator.","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 325 weeks","title":"Part A: Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}